Hematology-Oncology group photo

The Duke Hematology-Oncology Fellowship program provides clinical, translational, and basic laboratory training in hematology, medical oncology, cell therapy and bone marrow transplantation. Program resources include more than 100 full-time faculty in the Divisions of Medical Oncology, Hematological Malignancies and Cellular Therapy, and Hematology. The Fellowship has an average of 21 fellows in different stages of training.

Mission:

Learn more

Hear from Program Director Richard Riedel, MD

Program Leadership

Richard Riedel

Richard F. Riedel, MD
Program Director, Hematology-Oncology Fellowship
Associate Professor of Medicine 
Division of Medical Oncology
Duke University Medical Center
Email: richard.riedel@duke.edu 

Gowthami Arepally

Gowthami M. Arepally, MD
Associate Program Director, Hematology-Oncology Fellowship
Professor of Medicine and Pathology
Division of Hematology
Duke University Medical Center
Email: gowthami.arepally@duke.edu

Nyasia Lloyd
Program Coordinator, Hematology-Oncology Fellowship
Phone: 919-684-2287
Email: nyasia.lloyd@duke.edu

Latest News

Two faculty in the Department of Medicine have received Career Development Awards from the U.S. Department of Veterans Affairs.

Charity Oyedeji, MD, has received a Duke REACH Equity 2021 Career Development Award for her project "Sickle cell disease functional assessment validation and refinement (SILVR) study," with mentor JJ Strouse, MD, PhD. 

Charity Oyedeji, MD, a senior fellow in the Division of Hematology, is exploring the intersection of geriatrics and sickle cell disease. It’s a new field because in the past, most people with the disease did not reach adulthood.

The Duke UNC-Chapel Hill Immunotherapy Training Grant (DUNC-IMTG) is accepting applications for the 2020-2021 admission cycle. DUNC-IMTG is a combined training program from the University of North Carolina at Chapel Hill and Duke University that will focus on training individuals in translational and/or clinical research focusing on tumor immunology and cellular immunotherapy. Applications are due June 15, 2020.